Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 45

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Chronic rhinosinusitis with nasal polyps

Not yet recruiting

Comparison of dupilumab and tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Vienna

Lung neoplasm malignant

Not yet recruiting

Study of osimertinib and febuxostat to improve drug delivery in patients with EGFR-mutated non-small cell lung cancer without brain metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Febuxostat
  • Sponsor:Academisch Ziekenhuis Maastricht

Chronic obstructive pulmonary disease

Not yet recruiting

Study of the effect of lyophilized bacterial lysates on reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD)

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Semmelweis University

Post-acute COVID-19 syndrome

Not yet recruiting

A study to evaluate the effectiveness of upadacitinib and pirfenidone in reducing symptom severity in patients with Long Covid

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Pirfenidone
  • Sponsor:Dr. Douglas D. Fraser

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Endometrial cancer+7

Not yet recruiting

A study to evaluate the safety of SGN-ALPV in patients with advanced solid tumors

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:SGN-ALPV
  • Sponsor:Seagen Inc.

Lung cancer metastatic

Not yet recruiting

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Chronic obstructive pulmonary disease

Not yet recruiting

Study of RSV vaccine and pneumococcal vaccine combination for patients aged 60 and older with chronic obstructive pulmonary disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Nordsjaellands Hospital

COVID-19

Not yet recruiting

Study of Intravenous Immunoglobulin Added to Standard Treatment for COVID-19 in Patients with Severely Weakened Immune System Due to B-cell Problems

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Region Vaesterbotten

Malignant pleural effusion

Not yet recruiting

A Study of Pressurized Aerosol Chemotherapy with Cisplatin and Doxorubicin for Patients with Fluid Buildup Around the Lungs Caused by Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Azienda Ospedaliero Universitaria Pisana

Tracheobronchitis bacterial

Not yet recruiting

A study testing inhaled amikacin compared to placebo in critically ill patients with ventilator-associated tracheobronchitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.